Paper19320232
Simplification strategies to reduce antiretroviral drug exposure: progress and prospects.
McKinnon JE and 2 others. Antivir Ther, 2009. Cited by 30 papers, by iCite.
Cite this record
ConductScience Library. Simplification strategies to reduce antiretroviral drug exposure: progress and prospects. Papers, record 19320232. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19320232
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Simplification strategies to reduce antiretroviral drug exposure: progress and prospects.
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anti-HIV Agents | Major topic |
| HIV Infections | Major topic |
| HIV Protease Inhibitors | Major topic |
| HIV-1 | Major topic |
| Reverse Transcriptase Inhibitors | Major topic |
| Administration, Oral | |
| Antiretroviral Therapy, Highly Active | |
| Drug Administration Schedule | |
| Drug Combinations | |
| Drug Resistance, Multiple, Viral | |
| Drug Therapy, Combination | |
| Forecasting | |
| Humans | |
| Medication Adherence | |
| Randomized Controlled Trials as Topic | |
| Ritonavir |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| KL2 TR000146 | NCATS NIH HHS | United States | KL2TR000146 | PubMed and NIH | NIH RePORTER |
| T32 AI007333 | NIAID NIH HHS | United States | T32AI007333 | PubMed and NIH | NIH RePORTER |
References55
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 16267763 | Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. | J Infect Dis | 2005 | https://conductscience.org/library/papers/16267763 | PubMed |
| 2 | 12001042 | A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. | J Infect Dis | 2002 | https://conductscience.org/library/papers/12001042 | PubMed |
| 3 | 15798380 | Early virologic failure in a pilot study evaluating the efficacy of therapy containing once-daily abacavir, lamivudine, and tenofovir DF in treatment-naive HIV-infected patients. | AIDS Patient Care STDS | 2005 | https://conductscience.org/library/papers/15798380 | PubMed |
| 4 | 17617270 | Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. | Lancet | 2007 | https://conductscience.org/library/papers/17617270 | PubMed |
| 5 | 10601505 | Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. | N Engl J Med | 1999 | https://conductscience.org/library/papers/10601505 | PubMed |
| 6 | 14668455 | Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. | N Engl J Med | 2003 | https://conductscience.org/library/papers/14668455 | PubMed |
| 7 | 12153332 | Clinical implications of CNS penetration of antiretroviral drugs. | CNS Drugs | 2002 | https://conductscience.org/library/papers/12153332 | PubMed |
| 8 | 17117019 | The level of persistent HIV viremia does not increase after successful simplification of maintenance therapy to lopinavir/ritonavir alone. | AIDS | 2006 | https://conductscience.org/library/papers/17117019 | PubMed |
| 9 | 17001298 | A once-daily combination tablet (Atripla) for HIV. | Med Lett Drugs Ther | 2006 | https://conductscience.org/library/papers/17001298 | PubMed |
| 10 | 9683207 | Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study. | Lancet | 1998 | https://conductscience.org/library/papers/9683207 | PubMed |
| 11 | 11734634 | Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters. | Proc Natl Acad Sci U S A | 2001 | https://conductscience.org/library/papers/11734634 | PubMed |
| 12 | 17461744 | Monotherapy with lopinavir/ritonavir. | Expert Opin Investig Drugs | 2007 | https://conductscience.org/library/papers/17461744 | PubMed |
| 13 | 17434845 | Pilot study of a novel short-cycle antiretroviral treatment interruption strategy: 48-week results of the five-days-on, two-days-off (FOTO) study. | HIV Clin Trials | 2007 | https://conductscience.org/library/papers/17434845 | PubMed |
| 14 | 12514410 | Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. | J Acquir Immune Defic Syndr | 2003 | https://conductscience.org/library/papers/12514410 | PubMed |
| 15 | 17159658 | Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy. | J Acquir Immune Defic Syndr | 2007 | https://conductscience.org/library/papers/17159658 | PubMed |
| 16 | 16807250 | Benefits and concerns of simplification strategies in HIV-infected patients. | J Antimicrob Chemother | 2006 | https://conductscience.org/library/papers/16807250 | PubMed |
| 17 | 16452065 | Higher virological effectiveness of NNRTI-based antiretroviral regimens containing nevirapine or efavirenz compared to a triple NRTI regimen as initial therapy in HIV-1-infected adults. | HIV Clin Trials | 2005 | https://conductscience.org/library/papers/16452065 | PubMed |
| 18 | 11596076 | Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen. | J Med Virol | 2001 | https://conductscience.org/library/papers/11596076 | PubMed |
| 19 | 11192858 | The ADAM study continued: maintenance therapy after 50 weeks of induction therapy. | AIDS | 2001 | https://conductscience.org/library/papers/11192858 | PubMed |
| 20 | 18097218 | Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV. | AIDS | 2008 | https://conductscience.org/library/papers/18097218 | PubMed |
Cited by15
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 30 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41601776 | Pharmacoeconomic perspectives on HIV: integrating data for long-term treatment and prevention. | Front Med (Lausanne) | 2025 | https://conductscience.org/library/papers/41601776 | PubMed |
| 41498461 | Effectiveness and safety of two-drug regimens containing an integrase inhibitor and reverse transcriptase inhibitor in a cohort of virologically suppressed people with HIV: Data from the COMBINE-2 study. | HIV Med | 2026 | https://conductscience.org/library/papers/41498461 | PubMed |
| 31802641 | Two-drug antiretroviral regimens: an assessment of virologic response and durability among treatment-experienced persons living with HIV in the OPERA® Observational Database. | J Int AIDS Soc | 2019 | https://conductscience.org/library/papers/31802641 | PubMed |
| 25924841 | HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial. | Retrovirology | 2015 | https://conductscience.org/library/papers/25924841 | PubMed |
| 24802242 | Baseline natural killer and T cell populations correlation with virologic outcome after regimen simplification to atazanavir/ritonavir alone (ACTG 5201). | PLoS One | 2014 | https://conductscience.org/library/papers/24802242 | PubMed |
| 24777106 | Enhanced antiretroviral therapy in rhesus macaques improves RT-SHIV viral decay kinetics. | Antimicrob Agents Chemother | 2014 | https://conductscience.org/library/papers/24777106 | PubMed |
| 22646049 | Unboosted atazanavir for treatment of HIV infection: rationale and recommendations for use. | Drugs | 2012 | https://conductscience.org/library/papers/22646049 | PubMed |
| 21931626 | Calculation of direct antiretroviral treatment costs and potential cost savings by using generics in the German HIV ClinSurv cohort. | PLoS One | 2011 | https://conductscience.org/library/papers/21931626 | PubMed |
| 21910865 | Kinetics of the viral cycle influence pharmacodynamics of antiretroviral therapy. | Biol Direct | 2011 | https://conductscience.org/library/papers/21910865 | PubMed |
| 21886816 | Pilot, randomized study assessing safety, tolerability and efficacy of simplified LPV/r maintenance therapy in HIV patients on the 1 PI-based regimen. | PLoS One | 2011 | https://conductscience.org/library/papers/21886816 | PubMed |
| 21845035 | Treatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs. | Patient Prefer Adherence | 2011 | https://conductscience.org/library/papers/21845035 | PubMed |
| 21817194 | Single genome sequencing of HIV-1 gag and protease resistance mutations at virologic failure during the OK04 trial of simplified versus standard maintenance therapy. | Antivir Ther | 2011 | https://conductscience.org/library/papers/21817194 | PubMed |
| 20701796 | Evaluation of HIV protease and nucleoside reverse transcriptase inhibitors on proliferation, necrosis, apoptosis in intestinal epithelial cells and electrolyte and water transport and epithelial barrier function in mice. | BMC Gastroenterol | 2010 | https://conductscience.org/library/papers/20701796 | PubMed |
| 20213370 | Drug-drug interactions and adverse drug reactions: separating the wheat from the chaff. | Wien Klin Wochenschr | 2010 | https://conductscience.org/library/papers/20213370 | PubMed |
| 19958227 | NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery. | Nanomedicine (Lond) | 2009 | https://conductscience.org/library/papers/19958227 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD4 | 920 | PubTator's text mining | https://conductscience.org/library/genes/920 | NCBI Gene |
| MLC1 | 23209 | PubTator's text mining | https://conductscience.org/library/genes/23209 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/19320232
GET https://conductscience.org/api/papers/v1/19320232/references?page=2